Is Compounded Tirzepatide Going Away? What Actually Changed in October 2024

Not entirely. The shortage-based pathway ended October 2, 2024. The 503A patient-specific pathway continues for individualized clinical reasons.

When did tirzepatide come off the shortage list?
October 2, 2024.

Can pharmacies still compound tirzepatide?
Yes, 503A pharmacies can compound for individual patients with documented clinical justification.

What is the difference between 503A and 503B?
503A is patient-specific, regulated by state pharmacy boards. 503B is batch production, regulated by the FDA. Tirzepatide 503B compounding ended; 503A continues.

Is it legal to get compounded tirzepatide in 2026?
Yes, through a 503A pharmacy with a valid prescription documenting individualized clinical reason.

Will all compounded GLP-1 medications go away?
No. The 503A pathway is preserved by federal statute.

What clinical reasons justify compounded tirzepatide?
Allergen sensitivity to commercial inactive ingredients, dose individualization, concentration adjustment, preservative-free formulation.

Does FormBlends still offer compounded tirzepatide?
Yes, through 503A pharmacy partners for patients with documented clinical justification.

What happens if I'm currently on compounded tirzepatide?
Discuss with your prescriber whether continued use is clinically justified or whether a transition to brand product makes sense.

Is compounded tirzepatide the same as Zepbound?
Same active ingredient; different finished product. Not FDA-approved, not regulatorily equivalent.

Related guides

• Is Tirzepatide Going Away? Brand vs Compounded Availability in 2026
• Is Compounded Semaglutide Going Away? The February 2025 Decision Explained
• Is Semaglutide Going Away? The Brand vs Compounded Distinction in 2026
• Mounjaro Injection Price Equivalent: What You'll Actually Pay for Brand vs Compounded Tirzepatide in 2026
• Where to Get the Cheapest Compounded Tirzepatide in 2026 (And What "Cheapest" Actually Means)
• Cheap Compounded Tirzepatide in 2026: What "Affordable" Actually Means and When Low Price Signals Risk

Sources

1. FDA Drug Shortage List update, October 2, 2024, resolving tirzepatide shortage
2. FDA Guidance, "Compounding and the FDA: Questions and Answers," current as of 2025
3. Federal Food, Drug, and Cosmetic Act, Sections 503A and 503B, 21 U.S.C. § 353a-b
4. Food and Drug Administration Modernization Act of 1997 (Pub. L. 105-115)
5. Outsourcing Facilities Association v. FDA, U.S. District Court Northern District of Texas, ruling March 5, 2025
6. Jastreboff AM et al., "Tirzepatide Once Weekly for the Treatment of Obesity," New England Journal of Medicine, July 2022 (SURMOUNT-1)
7. USP General Chapter 797, Pharmaceutical Compounding - Sterile Preparations
8. USP General Chapter 795, Pharmaceutical Compounding - Nonsterile Preparations
9. Eli Lilly LillyDirect platform announcement, January 4, 2024
10. FDA Drug Safety Communication on compounded GLP-1 medications, 2024
11. Endocrine Society Clinical Practice Guideline on Obesity, 2023
12. National Association of Boards of Pharmacy, Model State Pharmacy Act and Model Rules, 2024 edition
13. Eli Lilly Q3 2024 manufacturing capacity update, investor relations

Footer disclaimers

Platform Disclaimer. FormBlends is a telehealth platform connecting patients with licensed clinicians and 503A compounding pharmacies. We do not practice medicine, dispense advice, or replace the prescriber-patient relationship. Eligibility, prescribing, and pharmacy fulfillment are independent clinical decisions.

Compounded Medication Notice. Compounded tirzepatide is prepared by a licensed pharmacy for an individual patient based on a valid prescription. It is not FDA-approved. It is not bioequivalent or interchangeable with brand-name Mounjaro or Zepbound in any regulatory sense. Clinical trial efficacy and safety data for tirzepatide apply to the Eli Lilly product specifically.

Results Disclaimer. Weight outcomes vary individually. Trial data summarized here describes group averages and does not predict your specific result. Plateau, regain after discontinuation, and adverse events all occur in real-world use.

Trademark Notice. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. LillyDirect is a service mark of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly.